Article
PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Scientific reports - 16 Mar 2021
Marayati Raoud, Stafman Laura L, Williams Adele P, Bownes Laura V, Quinn Colin H, Aye Jamie M, Stewart Jerry E, Yoon Karina J, Anderson Joshua C, Willey Christopher D, Beierle Elizabeth A
Abstract excerpt
Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with 54-80% of patients developing resistance to chemotherapy after 4-5 cycles of treatment. Stem cell-like cancer cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.